Product Detail
Product NameMAP3K8 (Ab-400) Antibody
Host SpeciesRabbit
ClonalityPolyclonal
PurificationThe antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
ApplicationsWB IHC
Species ReactivityHu
SpecificityThe antibody detects endogenous levels of total MAP3K8 protein.
Immunogen TypePeptide
Immunogen DescSynthesized non-phosphopeptide derived from human MAP3K8 around the phosphorylation site of serine 400 (C-Q-S(p)-L-D).
Target NameMAP3K8
ConjugateUnconjugated
Other NamesC-COT; cancer Osaka thyroid oncogene; COT proto-oncogene serine/threonine-protein kinase; EC 2.7.11.25; kinase Cot
Accession NoSwiss-Prot: P41279
NCBI Gene ID: 1326
Uniprot
P41279
Gene ID
1326;
Sdspage MW60kd
Concentration1.0mg/ml
FormulationRabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
StorageStore at -20˚C
Application Details
Western blotting: 1:500~1:3000
Immunohistochemistry: 1:50~1:100
Western blot analysis of extracts from COLO cells, treated with Insulin (0.01U/ml, 15mins), using MAP3K8 (Ab-400) antibody #33235.
Immunohistochemistry analysis of paraffin-embedded human brain tissue using MAP3K8 (Ab-400) antibody #33235.
Required for lipopolysaccharide (LPS)-induced, TLR4-mediated activation of the MAPK/ERK pathway in macrophages, thus being critical for production of the proinflammatory cytokine TNF-alpha (TNF) during immune responses. Involved in the regulation of T-helper cell differentiation and IFNG expression in T-cells. Involved in mediating host resistance to bacterial infection through negative regulation of type I interferon (IFN) production. In vitro, activates MAPK/ERK pathway in response to IL1 in an IRAK1-independent manner, leading to up-regulation of IL8 and CCL4. Transduces CD40 and TNFRSF1A signals that activate ERK in B-cells and macrophages, and thus may play a role in the regulation of immunoglobulin production. May also play a role in the transduction of TNF signals that activate JNK and NF-kappa-B in some cell types. In adipocytes, activates MAPK/ERK pathway in an IKBKB-dependent manner in response to IL1B and TNF, but not insulin, leading to induction of lipolysis. Plays a role in the cell cycle. Isoform 1 shows some transforming activity, although it is much weaker than that of the activated oncogenic variant.
Miyoshi J.,Mol. Cell. Biol. 11:4088-4096(1991).
Aoki M., J. Biol. Chem. 268:22723-22732(1993).
Chan A.M.,Oncogene 8:1329-1333(1993).
If you have published an article using product 33235, please notify us so that we can cite your literature.
et al,Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.In J Exp Clin Cancer Res. On 2018 Nov 27 by Qiang Z, Zhou ZY et al..PMID: 30482227
, (2018),
PMID:
30482227
et al,Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology. In Elife on 2021 Dec 7 by Timothy M Errington, Alexandria Denis,
et al..PMID:34874009
, (2021),
PMID:
34874009
Yes
